Eric D Hsi Selected Research

Vincristine (Oncovin)

1/2019	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
1/2019	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
12/2016	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
1/2016	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
10/2015	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
7/2014	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
11/2012	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
5/2012	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
12/2010	Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric D Hsi Research Topics

Disease

53	Neoplasms (Cancer) 04/2024 - 06/2002
38	Lymphoma (Lymphomas) 04/2024 - 01/2002
36	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2022 - 06/2006
18	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2007
12	Hodgkin Disease (Hodgkin's Disease) 10/2020 - 06/2005
11	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 07/2020 - 11/2008
10	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2023 - 08/2002
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 07/2005
8	Leukemia 01/2021 - 07/2005
7	T-Cell Lymphoma (Lymphoma, T Cell) 10/2023 - 01/2007
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2020 - 08/2004
6	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022 - 01/2007
6	Disease Progression 01/2018 - 08/2011
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2016 - 07/2005
6	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2014 - 10/2003
5	Multiple Myeloma 01/2020 - 08/2004
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2014 - 03/2003
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 05/2008
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 11/2022 - 01/2002
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2019 - 04/2011
2	B-Cell Leukemia (Leukemia, B Cell) 11/2020 - 06/2014
2	Neutropenia 10/2019 - 10/2019
2	Anemia 10/2019 - 01/2017
2	Infections 10/2017 - 04/2004
2	Residual Neoplasm 10/2017 - 04/2012
2	Genetic Translocation (Chromosomal Translocation) 10/2014 - 11/2009
2	Fever (Fevers) 01/2013 - 04/2004
2	Plasma Cell Neoplasms 08/2011 - 10/2009
1	Celiac Disease (Celiac Sprue) 11/2023
1	Sepsis (Septicemia) 08/2023
1	Polycythemia (Erythrocytosis) 01/2023
1	Colitis 09/2022

Drug/Important Bio-Agent (IBA)

21	Rituximab (Mabthera)FDA Link 01/2019 - 01/2008
20	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2006
14	Biomarkers (Surrogate Marker)IBA 08/2023 - 10/2004
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 12/2010
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 12/2010
9	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 12/2010
9	Prednisone (Sone)FDA LinkGeneric 01/2019 - 12/2010
7	Cyclin D1IBA 01/2019 - 04/2006
6	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 06/2002
6	AntibodiesIBA 01/2019 - 11/2003
6	Monoclonal AntibodiesIBA 11/2014 - 04/2004
5	enzastaurinIBA 01/2016 - 07/2009
5	ParaffinIBA 04/2015 - 03/2003
4	Immunoglobulins (Immunoglobulin)IBA 12/2023 - 03/2003
4	venetoclaxIBA 11/2020 - 10/2016
4	Bortezomib (Velcade)FDA Link 01/2020 - 08/2004
4	CyclinsIBA 01/2019 - 04/2006
4	Formaldehyde (Formol)FDA Link 04/2015 - 04/2006
3	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 01/2018
3	ibrutinibIBA 12/2019 - 03/2015
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 10/2019 - 08/2002
3	CytokinesIBA 01/2019 - 04/2007
3	LigandsIBA 01/2019 - 01/2008
3	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018 - 10/2003
3	Indicators and Reagents (Reagents)IBA 01/2017 - 07/2007
3	AntigensIBA 12/2016 - 04/2004
3	Histone Deacetylase InhibitorsIBA 10/2013 - 07/2010
3	Messenger RNA (mRNA)IBA 11/2009 - 03/2003
3	AnthracyclinesIBA 01/2008 - 08/2004
2	Histones (Histone)IBA 01/2023 - 07/2010
2	Hemoglobins (Hemoglobin)IBA 01/2023 - 04/2004
2	Complement System Proteins (Complement)IBA 11/2022 - 01/2010
2	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2018
2	Phosphotransferases (Kinase)IBA 01/2021 - 07/2007
2	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2021 - 09/2014
2	Cytidine DeaminaseIBA 01/2021 - 01/2016
2	IgKIBA 10/2019 - 11/2009
2	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2019 - 04/2006
2	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 05/2012
2	Anaplastic Lymphoma KinaseIBA 01/2019 - 08/2014
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018 - 05/2011
2	Leucine (L-Leucine)FDA Link 01/2018 - 01/2018
2	Immunoglobulin M (IgM)IBA 01/2018 - 10/2017
2	Vinblastine (Vinblastine Sulfate)FDA Link 01/2018 - 05/2011
2	Tyrosine Kinase InhibitorsIBA 01/2018 - 01/2016
2	Dacarbazine (DIC)FDA LinkGeneric 01/2018 - 05/2011
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018 - 10/2007
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2017 - 01/2016
2	NF-kappa B (NF-kB)IBA 12/2016 - 10/2003
2	Protein Kinase CIBA 01/2016 - 10/2013
2	MicroRNAs (MicroRNA)IBA 06/2015 - 07/2011
2	Immunoglobulin G (IgG)IBA 09/2013 - 01/2010
2	TWEAK ReceptorIBA 02/2013 - 01/2010
2	enavatuzumabIBA 02/2013 - 01/2010
2	Histone Deacetylases (Histone Deacetylase)IBA 09/2011 - 07/2010
2	Gemcitabine FDA Link 05/2011 - 06/2008
2	Thomsen-Friedenreich antibodiesIBA 11/2003 - 01/2002
1	Circulating Tumor DNAIBA 11/2022
1	CateninsIBA 09/2022

Therapy/Procedure

40	Therapeutics 04/2024 - 01/2002
13	Drug Therapy (Chemotherapy) 01/2023 - 01/2002
7	Stem Cell Transplantation 04/2024 - 11/2008
5	Immunotherapy 01/2019 - 01/2002
4	Radiotherapy 04/2024 - 09/2013
2	Precision Medicine 11/2022 - 01/2013
2	VAP-cyclo protocol 10/2015 - 12/2010
1	Investigational Therapies (Experimental Therapy) 11/2023
1	Photopheresis 11/2022